Gaps in surveillance, testing, sequencing, and vaccination for COVID-19 could create the perfect storm for a new variant.
To help address the need for more content-focused solutions to reach HCPs more effectively, Havas Health & You has formed a global partnership with Evermed, a technology company whose modular content hubs power personalized video content delivery for life science companies and HCPs.
The drug is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.
The number of people in Europe with undiagnosed HIV has risen as testing rates fell during the COVID-19 pandemic, threatening a global goal of ending the disease by 2030, a report said.
Britain is only marginally better prepared for another pandemic than it was for COVID-19, the former head of Britain’s vaccine taskforce said on Wednesday, criticizing how some structures that helped it emerge from the pandemic had been dismantled.
Matthew W. Reynolds, Ph.D., vice president, scientific affairs, real world solutions, IQVIA explains how RWE evidence platforms can provide a greater picture of a disease’s progression as well as a blueprint for future outbreaks.
England’s government agency responsible for responding to public health emergencies said mistakes at a testing laboratory resulted in tens of thousands of positive COVID-19 cases reported as negative may have led to the deaths of 20 people.
For years digital health platforms have been integral in helping navigate viral outbreaks such as HIV, COVID-19, and monkeypox. Ramin Bastani, CEO of Healthvana – a platform that delivers test results and records (the company just surpassed 50 million records delivered) to get patients on the right track to receive treatment – talks about how such digital health solutions are improving the response to disease outbreaks.
Dr. Anthony Fauci, the U.S. health official celebrated and vilified as the face of the country’s COVID-19 pandemic response, used his final White House briefing on Tuesday to denounce division and promote vaccines.
Regulators in Japan had previously denied emergency approval for the Shionogi pill, saying they wanted to see more data on its effectiveness. There were also concerns the drug could pose risk to pregnancies, based on results from animal studies.